PE20000017A1 - Combinaciones de estatina-eter carboxialquilico - Google Patents

Combinaciones de estatina-eter carboxialquilico

Info

Publication number
PE20000017A1
PE20000017A1 PE1998001207A PE00120798A PE20000017A1 PE 20000017 A1 PE20000017 A1 PE 20000017A1 PE 1998001207 A PE1998001207 A PE 1998001207A PE 00120798 A PE00120798 A PE 00120798A PE 20000017 A1 PE20000017 A1 PE 20000017A1
Authority
PE
Peru
Prior art keywords
alkyl
composition
carboxialkyl
dialuvastatin
fluvastatin
Prior art date
Application number
PE1998001207A
Other languages
English (en)
Spanish (es)
Inventor
Charles Larry Bisgaier
Roger Schofield Newton
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PE20000017A1 publication Critical patent/PE20000017A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
PE1998001207A 1997-12-12 1998-12-11 Combinaciones de estatina-eter carboxialquilico PE20000017A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6937597P 1997-12-12 1997-12-12

Publications (1)

Publication Number Publication Date
PE20000017A1 true PE20000017A1 (es) 2000-01-20

Family

ID=22088573

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998001207A PE20000017A1 (es) 1997-12-12 1998-12-11 Combinaciones de estatina-eter carboxialquilico

Country Status (30)

Country Link
EP (1) EP1045691B1 (cg-RX-API-DMAC7.html)
JP (1) JP2002508320A (cg-RX-API-DMAC7.html)
KR (1) KR20010033003A (cg-RX-API-DMAC7.html)
AR (1) AR017851A1 (cg-RX-API-DMAC7.html)
AT (1) ATE285762T1 (cg-RX-API-DMAC7.html)
AU (1) AU754089B2 (cg-RX-API-DMAC7.html)
BR (1) BR9813542A (cg-RX-API-DMAC7.html)
CA (1) CA2304612A1 (cg-RX-API-DMAC7.html)
CO (1) CO4970816A1 (cg-RX-API-DMAC7.html)
CR (1) CR5926A (cg-RX-API-DMAC7.html)
CU (1) CU20000140A7 (cg-RX-API-DMAC7.html)
DE (1) DE69828442T2 (cg-RX-API-DMAC7.html)
DK (1) DK1045691T3 (cg-RX-API-DMAC7.html)
ES (1) ES2230733T3 (cg-RX-API-DMAC7.html)
GT (1) GT199800196A (cg-RX-API-DMAC7.html)
HN (1) HN1998000185A (cg-RX-API-DMAC7.html)
HU (1) HUP0004547A3 (cg-RX-API-DMAC7.html)
IL (1) IL135349A0 (cg-RX-API-DMAC7.html)
IS (1) IS2150B (cg-RX-API-DMAC7.html)
MY (1) MY118381A (cg-RX-API-DMAC7.html)
NO (1) NO20002966L (cg-RX-API-DMAC7.html)
NZ (1) NZ503982A (cg-RX-API-DMAC7.html)
PA (1) PA8464601A1 (cg-RX-API-DMAC7.html)
PE (1) PE20000017A1 (cg-RX-API-DMAC7.html)
PL (1) PL341066A1 (cg-RX-API-DMAC7.html)
PT (1) PT1045691E (cg-RX-API-DMAC7.html)
SV (1) SV1998000146A (cg-RX-API-DMAC7.html)
UY (1) UY25299A1 (cg-RX-API-DMAC7.html)
WO (1) WO1999030704A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA9811348B (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861555B2 (en) 2000-01-25 2005-03-01 Warner-Lambert Company Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith
CA2299397A1 (en) * 1997-12-12 1999-06-24 Warner-Lambert Company Antihyperlipidemic statin-lp(a) inhibitor combinations
US20030105154A1 (en) 2001-10-24 2003-06-05 Bisgaier Charles Larry Statin-carboxyalkylether combinations
CZ20011035A3 (cs) * 1998-09-30 2001-10-17 Warner-Lambert Company Léčivo pro prevenci nebo oddálení revaskularizace pomocí katetru u pacientů postiľených chorobou koronární artérie
US6562864B1 (en) * 1999-09-02 2003-05-13 Drake Larson Catechin multimers as therapeutic drug delivery agents
IN191580B (cg-RX-API-DMAC7.html) * 1999-12-17 2003-12-06 Ranbaxy Lab Ltd
NZ519550A (en) 2000-01-25 2003-11-28 Warner Lambert Co Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith
AU2001256278A1 (en) * 2000-04-18 2001-10-30 Bayer Aktiengesellschaft Use of cse inhibitors for treating heart failure
CZ20023459A3 (cs) * 2000-04-26 2003-05-14 Warner-Lambert Company Antihypertensní činidla a jejich použití
US6689807B1 (en) * 2000-06-08 2004-02-10 Caritas St. Elizabeth's Medical Center Of Boston, Inc. HMG CoA reductase inhibitors for promoting angiogenesis
CA2450820C (en) * 2001-08-16 2011-03-15 Teva Pharmaceutical Industries Ltd. Processes for preparing calcium salt forms of statins
KR20040026705A (ko) 2001-08-16 2004-03-31 테바 파마슈티컬 인더스트리즈 리미티드 스타틴의 칼슘 염 형태의 제조 방법
US20050026979A1 (en) * 2003-07-31 2005-02-03 Maha Ghazzi Methods for treating inflammation and inflammation-associated diseases with a statin and ether
JP6295205B2 (ja) * 2012-01-06 2018-03-14 ジェムファイア セラピューティクス インクGemphire Therapeutics Inc. 心血管疾患のリスクを低減する方法
MX2018005096A (es) * 2015-11-06 2018-08-15 Gemphire Therapeutics Inc Combinaciones de gemcabeno para el tratamiento de enfermedad cardiovascular.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648387A (en) * 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases

Also Published As

Publication number Publication date
NO20002966D0 (no) 2000-06-09
IL135349A0 (en) 2001-05-20
JP2002508320A (ja) 2002-03-19
EP1045691B1 (en) 2004-12-29
IS5445A (is) 2000-04-14
ES2230733T3 (es) 2005-05-01
GT199800196A (es) 2000-06-03
SV1998000146A (es) 1999-09-30
WO1999030704A1 (en) 1999-06-24
EP1045691A1 (en) 2000-10-25
HN1998000185A (es) 1999-06-02
CR5926A (es) 2000-03-06
DE69828442D1 (de) 2005-02-03
CA2304612A1 (en) 1999-06-24
KR20010033003A (ko) 2001-04-25
NO20002966L (no) 2000-06-09
BR9813542A (pt) 2000-10-10
AU1591599A (en) 1999-07-05
HUP0004547A3 (en) 2001-12-28
IS2150B (is) 2006-10-13
PA8464601A1 (es) 2001-12-14
MY118381A (en) 2004-10-30
CO4970816A1 (es) 2000-11-07
NZ503982A (en) 2002-03-28
PL341066A1 (en) 2001-03-26
AR017851A1 (es) 2001-10-24
ATE285762T1 (de) 2005-01-15
DK1045691T3 (da) 2005-03-14
ZA9811348B (en) 1999-06-14
PT1045691E (pt) 2005-03-31
CU20000140A7 (es) 2005-10-19
HUP0004547A2 (hu) 2001-05-28
AU754089B2 (en) 2002-11-07
DE69828442T2 (de) 2005-06-02
UY25299A1 (es) 2001-08-27

Similar Documents

Publication Publication Date Title
ATE380020T1 (de) Stabile arzneiformulierungen enthaltend pravastatin or atorvastatin
AR018777A1 (es) Composicion farmaceutica que contiene una combinacion de una estatina y aspirina y metodo.
MX2009003920A (es) Estatina y acidos grasos omega 3 para reducir los niveles de apo b.
PE20060465A1 (es) Composiciones que contienen policosanol y un inhibidor de reductasa hmg-coa
PE20020850A1 (es) Utilizacion de compuestos de azetidinona sustituida para tratamiento de la sitosterolemia
DK1200385T3 (da) Krystaller af natriumsalt af pravastatin
IS2113B (is) Ný sölt HMG-CoA redúktasatálma
PE20050128A1 (es) Formulacion farmaceutica
SI1292293T1 (en) Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
MX9702175A (es) Combinacion de un inhibidor de absorcion de colesterol y un inhibidor de sintesis de colesterol.
AR045828A1 (es) Inhibidores de 3- hidroxi-3-metilglutaril -coenzima a reductasa
RU2004139029A (ru) Применение замещенных цианопирролидинов и содержащих их комбинированных препаратов для лечения гиперлипидемии и ассоциированных заболеваний
WO2000048626A3 (en) Aerosol compositions of hmg-coa reductase inhibitors for inhibiting inflammation associated with pulmonary disease
PA8464601A1 (es) Combinaciones de estatina-eter carboxialquilico
ATE444299T1 (de) Neue boronatester
PE20000348A1 (es) Composicion farmaceutica que comprende un inhibidor de metaloproteasa de matriz (mmp) y una estatina
CO5611117A2 (es) Combinacion de compuestos organicos
JP2003524582A5 (cg-RX-API-DMAC7.html)
BR0210426A (pt) Metil análogo de sinvastatina para inibição de hmg-coa redutase e processo de obtenção do mesmo
ECSP992883A (es) Composicion farmaceutica que contiene una combinacion de una estatina y aspirina y metodo
TH39048B (th) 2-อะเซติดิโนนที่ถูกแทนที่ด้วยน้ำตาลที่มีประ?โยชน์เป็นสารภาวะเลือดมีคลอเลสเตอรอลต่ำกว่าปกติ(Sugar-Substituted 2-Azetidinones Useful As Hypocholesterolemic Agents)
TH62472A (th) 2-อะเซติดิโนนที่ถูกแทนที่ด้วยน้ำตาลที่มีประ?โยชน์เป็นสารภาวะเลือดมีคลอเลสเตอรอลต่ำกว่าปกติ(Sugar-Substituted 2-Azetidinones Useful As Hypocholesterolemic Agents)
ECSP982777A (es) Combinaciones de estatina- - eter carboxialquilico.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed